FDA Safety Information

Zanaflex: Acorda Therapeutics and FDA informed health care professionals of changes to the contraindications and warnings  Sections of the product labeling

Zanaflex, a drug used to treat spasticity, In pharmacokinetic studies where tizanidine was coadministered with either fluvoxamine or ciprofloxacin (CYP1A2 inhibitors), the serum concentration of tizanidine was significantly increased and potentiated its hypotensive and sedative effects. Although there are no clinical studies evaluating the effects of other CYP1A2 inhibitors on tizanidine, coadministration of tizanidine with other CYP1A2 inhibitors (zileuton, other fluroquinolones, antiarrythmics, cimetidine, famotidine, oral contraceptives, acyclovir and ticlopidine) should be avoided.

Read the complete MedWatch 2007 Safety summary, including a link to the manufacturer's Dear Healthcare Provider Letter regarding this issue at:

www.fda.gov/medwatch/safety/2007/safety07.htm#Zanaflex